Early Diagnosis of Postoperative Acute Renal Failure-using Biomarker to Predict Outcome of Cardiac Surgery Associated Acute Kidney Injury (NSARF)
Recruitment status was Recruiting
The purpose of this study is to determine soluble HJV could be an early diagnosis urinary biomarker of ischemia/reperfusion injury in post CPB-patients.
Acute Renal Failure
Acute Kidney Injury
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||Early Diagnosis of Postoperative Acute Renal Failure - Using Biomarker to Predict the Outcome of Cardiac Surgery Associated Acute Kidney Injury|
Blood samples are drawn before the first dialysis session after postcardiac sugary associated severe AKI ( initializing RRT). Blood is drawn into Vacutainer tubes containing EDTA, and immediately placed on ice and centrifuged within 1 h. All the samples are stored at -70°C until analysis.
|Study Start Date:||June 2011|
|Estimated Study Completion Date:||July 2012|
|Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
Acute kidney injury (AKI) is a common syndrome on Intensive Care Unit, and renal dysfunction would result in a further morbidity and mortality. Critical ills complicated with acute kidney injury are usually accompanied with multi-organ failure. Therefore, National Taiwan University Hospital Study group of Acute Renal Failure (NSARF) realizes that the characteristics of AKI is resulted from the perfusion less of body fluid and attempt to develop therapies to prevent or attenuate AKI, which have had limited success. We attempt to use the novel biomarker soluble hemojuvelin (sHJV) to evaluate the iron homeostasis on acute kidney injury and develop new strategies and therapies such as protease inhibitors on kidney function, as safety markers to monitor toxicity and as measures of treatment effect. Besides, we will focus on validation the sensitivity and specificity of sHJV on the clinical specimen of post-operative patients from NSARF data-bank. Merge the renal function and other types of biomarkers as panel to predict the post-operative outcome. Based on the different expression of these markers, using a panel of serum and urine markers may potentially help us to distinguish between various types of insults, establish the duration and severity of injury, predict the clinical outcome and help to monitor response to treatment in AKI.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01503710
|Contact: G H Young, Ph.D.||886-2-2312-3456 ext firstname.lastname@example.org|
|Contact: W J Ko, M.D.,Ph.D.||886-2-2312-3456 ext email@example.com|
|Taipei, Taiwan, 10002|
|Contact: W J Ko, M.D., Ph.D. 886-2-2312-3456 ext 63098 firstname.lastname@example.org|
|Principal Investigator:||V C Wu, M.D., Ph.D.||Section of Nephrology, Department of Internal Medicine, National Taiwan University Hospital|